MBX Biosciences (NYSE:MBX) (NYSE:MBX) is a specialized contract research organization (CRO) that provides preclinical research services to biopharmaceutical and biotechnology companies. The company focuses on oncology and immuno-oncology, offering a range of in vivo and ex vivo models designed to accelerate drug discovery and development. Its scientific teams integrate advanced pharmacology, immunophenotyping and biomarker analysis to support translational research programs.
The company’s service portfolio includes custom animal model development, efficacy and toxicology studies, pharmacokinetic and pharmacodynamic assessments, and immune cell profiling. MBX Biosciences collaborates with small biotech firms, large pharmaceutical corporations and academic institutions to deliver tailored solutions for target validation, lead optimization and IND-enabling studies. With state-of-the-art laboratories and animal vivariums, the company maintains rigorous quality standards and regulatory compliance.
Founded in 2008, MBX Biosciences has grown from a single research site into an international platform, serving clients across North America, Europe and Asia. The company completed its initial public offering in late 2020, leveraging public capital to expand capacity, invest in automation and broaden its model portfolio. Strategic partnerships and targeted investments have enhanced its capabilities in immuno-oncology, cell therapy and rare disease models.
Under the leadership of an experienced management team with deep expertise in pharmaceutical development and biotechnology operations, MBX Biosciences continues to refine its service offerings and pursue global growth. The company’s ongoing commitment to scientific excellence, operational rigor and client collaboration positions it as a key partner for drug developers seeking to streamline preclinical workflows and accelerate time to clinic.
